Kechuang Bio has completed all the listing procedures, and the listing date is set for October 8, the first working day after the long holiday.
The agency has obtained the shipment volume of brain-computer interface mobile phones in China in the third quarter.
IDG, as one of the shareholders of Sci-Tech Biotech, separately listed brain-computer interface phones in its internal smartphone shipment report for calculation.
According to statistics, the shipment volume of brain-computer interface mobile phones in the first three quarters of 2021 reached 4.71 million units, far exceeding expectations.
Because the first brain-computer interface phone, the Mi Mix 4, was only launched in June, the brain-computer interface phone only had a sales period of one quarter.
The organization internally expects that the total shipment of brain-computer interface phones in 2022 will be around 20 million units, which can be considered an excellent result.
It's worth noting that in the third quarter of 2021, Apple, the biggest player in the high-end market, had not yet released its brain-computer interface phone.
Production capacity for brain-computer interface devices connected to mobile phones has exceeded expectations, albeit by a small margin.
Apple's fall launch event date hasn't been set yet, but Tim Cook has already started building hype on Twitter:
"The new iPhone is an unbelievably perfect product!"
"I can't wait to let you use it."
Due to technological limitations, brain-computer interface phones are basically only sold in China. Foreign consumers who want to use them either have to source the product from overseas or purchase it through a proxy.
This has led to the formation of a complete industrial chain, from purchasing brain-computer interfaces for mobile phones in China to exporting them to America, Europe, and other places.
Although English speakers or speakers of other languages only achieve a 70% accuracy rate in brain-computer interface recognition with mobile phones, the wealth of electronics enthusiasts in Europe and America is undeniable.
For an extra 200 yuan, they can enjoy brain-computer interface functionality. The brain-computer interface device is not much different from headphones, which is perfectly acceptable to them.
Cook's tweets were flooded with sarcastic comments:
"Another special supply for China"
"Apple only cares about the Chinese market."
"Brain-computer interface with mobile phone is indeed very convenient. I have a great experience using a Chinese-made brain-computer interface with mobile phone. It would be even better if the accuracy could be higher. When will Amerex's product be completed?"
Because of the better-than-expected shipments of brain-computer interface phones, institutions have raised the internal valuation of Kechuang Bio to another level.
“If we are considering the long term, we can buy Kechuang Bio without hesitation if the price is below 3,000 yuan.”
"Considering the short term, as long as the price doesn't reach 2,000 yuan on the first day of listing, we can build a position," a fund manager said at an internal investment research meeting.
"What if it hits 3,000 yuan on the first day of trading?" his assistant asked.
"Then let's wait for it to fall; we're not in a hurry to build a position."
"Unless we can get inside information about the research and development progress in the field of brain-computer interface technology for biotechnology," the fund manager thought. "Logically, it shouldn't be that difficult; based on my understanding, it should be soon."
"Unfortunately, our scale is too large, so we can't be aggressive. If it were a private equity fund, they would dare to go for it at a price of 3,000 yuan."
The assistant nodded and said, "Ever since the theft at the R&D center of Kechuang Bio in Singapore, they have changed their security personnel, hiring a domestic security company based in Singapore."
"It's even harder to get information now. Because Zheng Li is in Singapore, the progress of the Singapore R&D center won't be reported to Suzhou."
This fund manages over 50 billion yuan, making it one of the top funds in China, not far behind the hundreds of billions of yuan managed by Ge Lan and Zhang Kun.
The larger the assets under management, the more restrictions fund managers face in their operations. For example, Zhang Kun's rules only allow him to buy and sell about one hundred stocks.
Basically, you can only buy large-cap stocks and blue-chip stocks.
Fund managers are having a headache: "If Kechuang Bio's brain-computer interface technology makes progress before the first half of next year, whether it's the completion of R&D for English-language products or new applications of brain-computer interfaces in the medical field."
"I believe there is huge room for growth."
......
With the listing of Kechuang Biotechnology, Cheng Gang's career also reached its peak, and he felt for the first time that starting a business was such a simple thing.
After only some administrative work, Kechuang Bio is about to go public with a market value of 400 billion RMB, and the secondary market even thinks that the price is too cheap.
Cheng Gang gained a deeper understanding of the fact that science and technology are the primary productive forces. He realized that his own entrepreneurial failure was due to insufficient technological advantages.
Since Zheng Liyuan left for Singapore, Cheng Gang has effectively become the top figure at the headquarters of Kechuang Biotechnology. Gradually, he began to rival Li Miaomiao, Zheng Liyuan's spokesperson in the company.
Since Zheng Li remains the absolute controller of the company, even after Kechuang Bio goes public, Zheng Li will still hold more than 51% of the shares.
So Cheng Gang and Li Miaomiao appeared to be on good terms, but in private, they were each vying for the support of the company's middle management and other senior executives.
Although Zheng Li was far away in Singapore, he was fully aware of the company's situation. He knew what they knew, and he also knew what they didn't know.
On the eve of the IPO, financial institutions that wanted to engage in underhanded dealings approached not only Li Miaomiao, but also other senior executives of Kechuang Biotechnology.
Some executives couldn't resist the temptation and chose to accept the other party's sweet talk. Zheng Li didn't go through anyone and went directly through official channels to send the two to be investigated.
After this incident, the company's senior executives were shocked by Zheng Li's ruthlessness, and the company, which had been somewhat turbulent, calmed down again.
Cheng Gang no longer dared to try to win over senior and middle management. He realized that even without Zheng Li, he would only be a manager and would not become the actual controller of Kechuang Biotechnology.
Realizing that he was still just a manager, Cheng Gang chose to increase his interactions with Young at IDG.
“Young, after Kechuang Bio goes public, I plan to cash out some of my shares and establish a biopharmaceutical investment fund.”
"We can visit each other more often then."
If Cheng Gang were just a simple investment fund company owner, Young would certainly not have much contact with him, but Cheng Gang has another identity - the general manager of Kechuang Biotechnology.
“There’s a company that’s currently looking to raise Series C funding, but they have a huge funding gap. If you have any funds on hand, you might consider investing in it,” Young said.
Upon hearing about the Series C funding round and the large funding gap, Cheng Gang quickly realized: "Abogen Biosciences?"
Young nodded: "Yes, it's Abogen Biosciences. They're raising over 700 million US dollars in their Series C funding round, and seven funds have already led the investment."
“Temasek, Invesco Development Markets Fund, Zhenxin Capital, Hillhouse Capital, Lilly Asia Ventures and Yunfeng Capital.”
Some people believe that angel investment funds established by internet companies will not invest in the biopharmaceutical industry, but Yunfeng Capital, as the angel investment company of AliMa, participated in leading the Series C funding round of Abogen Biosciences.
To put it simply, angel investors only look at the quality of a project; they don't have clear standards for what not to invest in and what to invest in.
Lei Jun's Shunwei Capital's previous investment in Kechuang Bio was based on very realistic considerations.
Continue read on readnovelmtl.com
